患者的炎症和纤维化生物标志物 亚托皮炎患者接受 cendakimab 治疗
Jie Li1, Coryandar Gilvary1, Lu Gao1
1Bristol Myers Squibb, Princeton, NJ.
The journal of allergy and clinical immunology. Global
|December 26, 2025
概括
在中度至重度亚托皮性皮炎 (AD) 患者中,Cendakimab有效降低了关键的炎症和纤维化生物标志物. 这项为期16周的研究显示,与安慰剂相比,生物标志物水平显著下降.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亚托匹性皮肤炎 (AD) 病原发生涉及细胞因子IL-13.
- 仙达基马布是一种针对IL-13的单克隆抗体.
研究的目的:
- 为了评估由cendakimab抑制IL-13的药理学效应.
- 为了评估AD患者血清炎症和纤维化生物标志物的变化.
主要方法:
- 第二阶段,随机,双盲,安慰剂对照试验.
- 中度至重度AD的成年人接受 cendakimab (360毫克或720毫克) 或安慰剂皮下治疗16周.
- 分析了包括eotaxin-3,periostin,IL-18和CCL化学因子在内的血清生物标志物.
主要成果:
- 从第1-4周到第16周,Cendakimab显著降低了炎症和纤维化的生物标志物.
- 所有测试的仙达基马布剂量都显示出显著的减少.
- 与安慰剂相比,减少的幅度显著增加.
结论:
- 治疗Cendakimab导致关键炎症和纤维化生物标志物的水平降低.
- 这项研究支持sendakimab在治疗中度至重度亚托邦性皮炎方面的潜力.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
437
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
437
The JAK-STAT Signaling Pathway
11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.8K


